- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Status
Completed
Phase
Open Label
Principal Investigator(s)
Craig W. Hendrix
Objective
To determine the adherence acceptability to and blood levels of three daily regimens of tenofovir in both oral and gel form.
Results:Compared to oral dosing, vaginal dosing achieved much lower serum concentrations and much higher vaginal tissue concentrations. Even allowing for 100-fold concentration differences due to poor adherence or less frequent prescribed dosing, vaginal dosing of tenofovir should provide higher active site concentrations and theoretically greater PrEP efficacy than oral dosing; randomized topical dosing PrEP trials to the contrary indicates that factors beyond tenofovir's antiviral effect substantially influence PrEP efficacy.
Prevention Option(s)
Microbicides
Study Design
Open label
Arms and Assigned Interventions
Description
Oral tenofovir disoproxil fumarate (TDF) for Weeks 1 through 6, vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF and vaginal tenofovir gel application for Weeks 15 through 20
Mode of Delivery
Gel
Tablet
Products
1% tenofovir gel
TDF
ARMs
Experimental
Official Code
Trial Sponsors
NIAID, MTN, CONRAD, Gilead
June 2008
July 2010
Enrollment
168
18
Years
45
Years
Population
Women
Sites
Bronx-Lebanon Hospital
New York, New York
United States of America
Case CRS
Cleveland, Ohio
United States of America
Botha's Hill CRS
Westville, KwaZulu-Natal
South Africa
Umkomaas CRS
Umkomaas, KwaZulu-Natal
South Africa
Makerere University - Johns Hopkins University Research Collaboration
Kampala
Uganda
Alabama Microbicide CRS
Birmingham, Alabama
United States of America
Bronx- Lebanon Hospital Center Clinical Research Site
Bronx, New York
United States of America
Pitt CRS
Pittsburgh, Pennsylvania
United States of America